Teva announces new analysis from European cohort of RIM-TD study

Teva announced that a new analysis from the European cohort of the RIM-TD open-label extension, or OLE, study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia, or TD, was associated with long term improvement of TD symptoms. The improvement in symptoms was sustained throughout the three-year study, and deutetrabenazine was well tolerated. The data were presented at the European College of Neuropsychopharmacology, or ECNP, annual congress in Milan. RIM-TD is a three-year study which enrolled patients who had completed one of the two pivotal deutetrabenazine phase 3 studies, ARM-TD6 and AIM-TD.7 Whilst RIM-TD was conducted in both the United States and Europe, the post hoc subgroup analysis focused on patients from the European countries. Treatment success was defined as ‘much improved’ or ‘very much improved’ on the Clinical Global Impression of Change or Patient Global Impression of Change. The majority of patients achieved treatment success with 65% of patients for CGIC and 56% for PGIC. Deutetrabenazine was generally well tolerated, regardless of which arm of the two Phase 3 trials the patients had previously been treated in. Deutetrabenazine has now been evaluated in ARM-TD, AIM-TD as well as RIM-TD, all of which demonstrated that the treatment provides rapid, sustained, and clinically meaningful improvements in motor function in patients with Tardive Dyskinesia.